Last reviewed · How we verify
prednisolone and mycophenolate mofetil
Prednisolone is a corticosteroid that suppresses the immune system by inhibiting the production of inflammatory cytokines, while mycophenolate mofetil is an immunosuppressant that inhibits the proliferation of T and B lymphocytes.
Prednisolone is a corticosteroid that suppresses the immune system by inhibiting the production of inflammatory cytokines, while mycophenolate mofetil is an immunosuppressant that inhibits the proliferation of T and B lymphocytes. Used for Prevention of organ rejection in transplant patients, Treatment of autoimmune diseases such as rheumatoid arthritis and lupus.
At a glance
| Generic name | prednisolone and mycophenolate mofetil |
|---|---|
| Sponsor | Hospital Authority, Hong Kong |
| Drug class | Corticosteroid and immunosuppressant |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Prednisolone works by binding to glucocorticoid receptors, which then translocate to the nucleus and inhibit the transcription of inflammatory genes. Mycophenolate mofetil, on the other hand, inhibits the enzyme inosine monophosphate dehydrogenase, which is necessary for the proliferation of T and B lymphocytes.
Approved indications
- Prevention of organ rejection in transplant patients
- Treatment of autoimmune diseases such as rheumatoid arthritis and lupus
Common side effects
- Nausea
- Diarrhea
- Hypertension
- Hyperglycemia
- Increased risk of infections
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (PHASE2, PHASE3)
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study (PHASE4)
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment (PHASE2)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants (PHASE2)
- Tocilizumab in Cardiac Transplantation (PHASE2)
- Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma (PHASE2)
- The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: